GO:0032688 negative regulation of interferon-beta production: Innate Immune Checkpoint, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032688 describes any process that stops, prevents, or reduces the frequency, rate, or extent of interferon-beta (IFN-beta) production, a central antiviral cytokine.
• Multiple layers of negative regulation exist, including alternative splicing of TRAF3, autophagic degradation of MAVS, and metabolite-driven suppression via itaconate or lactate [1,3,5,7].
• Key negative regulators include SESN1, TRIM13, YTHDF2, HSPA6, and KEAP1-Nrf2 signaling, which converge on STING1, MAVS, IRF3, or NF-kB pathways [1,2,3,4,5].
• Dysregulation of IFN-beta negative regulation contributes to viral persistence, autoimmune pathology, and cancer immune evasion [6,8].
• CRISPR knockout, point mutation, knock-in, and overexpression models are essential to dissect causal roles of candidate regulators in IFN-beta suppression [2,4,5].
• Understanding this process informs therapeutic strategies for infectious diseases, interferonopathies, and immuno-oncology [1,8].
Description
Interferon-beta (IFN-beta) is a critical type I interferon produced rapidly upon viral infection and is essential for mounting effective antiviral and immunomodulatory responses. However, uncontrolled IFN-beta production can lead to chronic inflammation and autoimmune pathology, necessitating tight negative regulation. The Gene Ontology term GO:0032688, negative regulation of interferon-beta production, encompasses all molecular events that attenuate the synthesis or secretion of this cytokine. This process is hijacked by numerous viruses to evade host immunity and is subverted in cancer to promote immune escape [2,3,5]. Studying the negative regulators of IFN-beta production is therefore central to understanding host-pathogen interactions, autoimmunity, and tumor immunology [1,4,8]. Recent advances have revealed diverse mechanisms, from metabolite sensing to selective autophagy, that converge on key signaling nodes such as STING1, MAVS, and IRF3 [1,3,4,5]. This article synthesizes current knowledge on the genes, mechanisms, and experimental models used to investigate GO:0032688.
negative regulation of interferon-beta production At A Glance
| GO ID | GO:0032688 |
|---|---|
| GO term | negative regulation of interferon-beta production |
| Ontology | biological_process |
| Synonym | inhibition of interferon-beta production; negative regulation of IFN-beta production; downregulation of interferon-beta production |
| Major function | Attenuation of IFN-beta synthesis and secretion to maintain immune homeostasis and limit immunopathology |
| Key regulators | SESN1, TRIM13, YTHDF2, HSPA6, KEAP1, TRAF3 (splice variants), and others [1,2,3,4,5,7] |
| Associated pathways | STING1, MAVS, IRF3, NF-kB, autophagic degradation, metabolite sensing [1,3,4,5] |
| Disease relevance | Viral persistence, autoimmune diseases, cancer immune evasion [2,3,6,8] |
What Is GO:0032688?
GO:0032688 is defined as any biological process that stops, prevents, or reduces the frequency, rate, or extent of interferon-beta production. This includes inhibition of IFN-beta gene transcription, mRNA stability, protein synthesis, and secretion. It is a negative regulatory process that acts as a brake on type I interferon responses to prevent excessive inflammation while allowing effective antiviral defense.
Why Is negative regulation of interferon-beta production Important in Cell Biology?
Negative regulation of IFN-beta production is essential for balancing antiviral immunity and preventing inflammatory damage. Viruses often exploit these pathways to establish persistent infections, while defects in negative regulation can cause interferonopathies and autoimmune diseases [6,8]. In cancer, suppression of IFN-beta production contributes to immune evasion and resistance to immunotherapy [1,8]. Thus, understanding GO:0032688 provides critical insights into host-pathogen interactions, autoimmunity, and cancer biology, and identifies potential therapeutic targets.
• Prevents excessive type I interferon responses that can cause tissue damage and autoimmunity.
• Mediates viral immune evasion, as seen with foot-and-mouth disease virus, PRRSV, and avian viruses [2,3,5].
• Regulates the duration and magnitude of antiviral immunity to avoid chronic inflammation.
• Influences cancer immunosurveillance and response to immune checkpoint blockade [1,8].
• Provides targets for treating interferonopathies such as Aicardi-Goutieres syndrome.
• Involved in metabolic regulation of immunity via itaconate and lactate [1,3].
• Key to understanding species-specific differences in IFN-beta regulation, e.g., in ducks.
• Offers opportunities for host-directed antivirals that modulate IFN-beta without causing toxicity [2,4].
• Relevant to vaccine adjuvant design and innate immune training.
• Critical for maintaining immune homeostasis in barrier tissues.
What Happens During negative regulation of interferon-beta production?
Transcriptional suppression of IFN-beta gene expression
In simple terms: The cell reduces the transcription of the gene that makes IFN-beta.
Negative regulation of IFN-beta production often begins at the transcriptional level. During acute and persistent virus infections, host factors can directly or indirectly inhibit the activation of transcription factors such as IRF3 and NF-kB, which are required for IFN-beta gene expression. For example, alternative splicing of TRAF3 in ducks generates a negative regulator that dampens IFN-beta promoter activation. Similarly, the metabolite itaconate activates Nrf2 via alkylation of KEAP1, leading to anti-inflammatory effects that include suppression of IFN-beta production.
Post-transcriptional and post-translational regulation of signaling adaptors
In simple terms: The cell degrades or modifies key signaling proteins to stop the IFN-beta production line.
Negative regulation can occur through targeted degradation of signaling adaptors. Avian TRIM13 targets MAVS for autophagic degradation, thereby attenuating antiviral innate immunity and IFN-beta production. Foot-and-mouth disease virus VP1 degrades YTHDF2 through autophagy to regulate IRF3 activity, impairing IFN-beta induction. Lactate-driven lactylation of HSPA6 promotes PRRSV replication by impairing IFN-beta production, illustrating metabolite-driven post-translational suppression.
Autophagy-mediated degradation of immune sensors
In simple terms: Autophagy acts as a disposal system that removes proteins needed to trigger IFN-beta.
Selective autophagy plays a central role in negative regulation of IFN-beta production. SESN1 negatively regulates STING1 to maintain innate immune homeostasis, likely by promoting its autophagic degradation. TRIM13 similarly mediates autophagic degradation of MAVS. YTHDF2 degradation via autophagy modulates IRF3 activity. These examples highlight autophagy as a convergent mechanism for shutting down IFN-beta production.
Metabolic and stress-responsive checkpoints
In simple terms: Cellular metabolism and stress signals can put the brakes on IFN-beta.
Metabolites such as itaconate and lactate act as negative regulators of IFN-beta production. Itaconate activates Nrf2 via KEAP1 alkylation, leading to anti-inflammatory gene expression that suppresses IFN-beta. Lactate promotes HSPA6 lactylation, which impairs IFN-beta production and favors PRRSV replication. These findings link cellular metabolism to the regulation of innate immunity.
Negative feedback by type I IFN signaling itself
In simple terms: Once IFN-beta is made, it can trigger signals that later turn down its own production.
Type I IFN signaling induces negative feedback regulators such as SOCS proteins and USP18, which attenuate the pathway and prevent sustained IFN-beta production. This feedback is essential to avoid chronic interferon responses and immunopathology. Dysregulation of this feedback loop can lead to interferonopathies.
Key Genes Involved in GO:0032688 negative regulation of interferon-beta production
The following genes and proteins have been experimentally implicated in the negative regulation of interferon-beta production, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SESN1 | Negatively regulates STING1 to maintain innate immune homeostasis | Autophagy-mediated control of IFN-beta; knockout models show enhanced IFN-beta |
| TRIM13 | Targets MAVS for autophagic degradation | Viral evasion; overexpression suppresses IFN-beta |
| YTHDF2 | Regulates IRF3 activity; degraded by FMDV VP1 via autophagy | m6A reader; links RNA modification to IFN-beta suppression |
| HSPA6 | Lactylation impairs IFN-beta production | Metabolic regulation; lactate-driven suppression |
| KEAP1 | Alkylation by itaconate activates Nrf2, suppressing IFN-beta | Metabolite sensing; anti-inflammatory pathway |
| TRAF3 | Alternative splicing generates negative regulator of IFN-beta | Duck-specific regulation; splice variants |
| STING1 | Target of SESN1-mediated negative regulation | Central adaptor; autophagy-dependent control |
| MAVS | Target of TRIM13-mediated autophagic degradation | Mitochondrial antiviral signaling; viral evasion |
| IRF3 | Transcription factor; activity modulated by YTHDF2 | Key IFN-beta inducer; post-translational regulation |
| Nrf2 | Transcription factor activated by itaconate; anti-inflammatory | Suppresses IFN-beta indirectly |
| SOCS1/3 | Negative feedback regulators of type I IFN signaling | Prevent sustained IFN-beta production |
| USP18 | Negative regulator of type I IFN signaling | Feedback inhibition; interferonopathies |
| FMDV VP1 | Viral protein that degrades YTHDF2 to regulate IRF3 | Viral evasion mechanism |
| PRRSV | Virus that exploits lactate-HSPA6 axis to impair IFN-beta | Viral pathogenesis |
| Avian TRIM13 | Bird ortholog that attenuates antiviral innate immunity | Species-specific regulation |
| Itaconate | Metabolite that activates Nrf2 via KEAP1 alkylation | Anti-inflammatory metabolite |
| Lactate | Metabolite that promotes HSPA6 lactylation | Metabolic suppression of IFN-beta |
How Is negative regulation of interferon-beta production Regulated?
The negative regulation of IFN-beta production is itself tightly regulated at multiple levels. Metabolites such as itaconate and lactate can post-translationally modify key proteins (KEAP1, HSPA6) to suppress IFN-beta [1,3]. Autophagy provides a regulated degradation route for signaling adaptors like MAVS and STING1 [4,5]. Alternative splicing of TRAF3 generates a dominant-negative regulator in ducks. Additionally, type I IFN signaling induces negative feedback via SOCS and USP18 to prevent excessive responses. These layers ensure that IFN-beta production is transient and proportionate to the threat.
negative regulation of interferon-beta production and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SESN1 | Innate immune homeostasis; viral susceptibility | SESN1 knockout cell line; STING1 reporter |
| TRIM13 | Viral evasion; avian immunity | TRIM13 overexpression in avian cells; MAVS degradation assay |
| YTHDF2 | FMDV replication; m6A regulation | YTHDF2 knockout; FMDV infection; IRF3 activity |
| HSPA6 | PRRSV replication; metabolic suppression | HSPA6 point mutant (lactylation site); PRRSV infection |
| KEAP1 | Inflammation; cancer; itaconate response | KEAP1 knockout; Nrf2 activation; IFN-beta reporter |
Viral immune evasion and persistence
Many viruses exploit negative regulation of IFN-beta production to evade host immunity. Foot-and-mouth disease virus VP1 degrades YTHDF2 to modulate IRF3 activity, impairing IFN-beta induction and promoting viral replication. PRRSV uses the lactate-lactylation-HSPA6 axis to suppress IFN-beta production. Avian TRIM13 targets MAVS for autophagic degradation, attenuating antiviral innate immunity. These mechanisms contribute to viral persistence and pathogenesis.
Autoimmune and interferonopathies
Defects in negative regulation of IFN-beta production can lead to excessive type I interferon signaling, which is associated with autoimmune diseases such as systemic lupus erythematosus and Aicardi-Goutieres syndrome. Negative feedback regulators like SOCS proteins and USP18 are critical for preventing interferonopathies. Understanding these pathways may reveal therapeutic targets for modulating IFN-beta in autoimmune conditions.
Cancer immune evasion
Suppression of IFN-beta production in the tumor microenvironment can promote immune evasion and resistance to immunotherapy [1,8]. Itaconate-mediated activation of Nrf2 via KEAP1 alkylation not only suppresses IFN-beta but also creates an anti-inflammatory milieu that may favor tumor growth. Targeting negative regulators of IFN-beta could enhance anti-tumor immunity.
From negative regulation of interferon-beta production-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate IFN-beta production? | CRISPR knockout of gene X in a reporter cell line (e.g., IFN-beta-luciferase) |
| Which domain of gene X is required for suppression? | Point mutation or domain deletion via CRISPR knock-in |
| Does a specific post-translational modification regulate gene X activity? | Knock-in of phospho/lactylation-null or mimetic mutations |
| Where does gene X localize during viral infection? | Tagged knock-in (e.g., GFP or HA) for imaging |
| Does overexpression of gene X suppress IFN-beta? | Stable overexpression cell line followed by viral infection |
| What is the transcriptional consequence of gene X loss? | RNA-seq and ATAC-seq in knockout vs wild-type cells |
How to Study the negative regulation of interferon-beta production Process
| Method | What It Measures | Typical Application |
|---|---|---|
| IFN-beta luciferase reporter | Transcriptional activity of IFN-beta promoter | High-throughput screening of regulators |
| RNA-seq | Global mRNA changes including IFN-beta and interferon-stimulated genes | Knockout vs wild-type comparison |
| Proteomics (LC-MS/MS) | Protein interactions and post-translational modifications | Identifying lactylation or ubiquitination targets |
| Immunoblotting | Protein stability and degradation of MAVS, STING1, IRF3 | Autophagy-mediated degradation assays |
| Confocal microscopy | Subcellular localization and colocalization with autophagosomes | Tagged knock-in imaging |
| qRT-PCR | IFN-beta mRNA levels | Validation of reporter assays |
| CRISPR screening | Genome-wide identification of negative regulators | Pooled sgRNA libraries with IFN-beta reporter |
| Flow cytometry | IFN-beta protein production at single-cell level | Intracellular staining after viral infection |
Reporter-based assays for IFN-beta production
Luciferase or fluorescent reporters driven by the IFN-beta promoter are widely used to measure changes in IFN-beta production. These assays can be combined with CRISPR knockout or overexpression of candidate regulators to assess their impact [4,6].
RNA sequencing and transcriptomics
RNA-seq can quantify IFN-beta mRNA and global transcriptional changes upon modulation of negative regulators. It is useful for identifying downstream pathways and validating knockout effects [6,7].
Proteomics and post-translational modification analysis
Mass spectrometry-based proteomics can identify interacting partners and post-translational modifications (e.g., lactylation, ubiquitination) on key regulators such as HSPA6 or MAVS [3,5].
Imaging and autophagy flux assays
Fluorescence microscopy with tagged proteins (e.g., GFP-MAVS, RFP-LC3) can visualize autophagic degradation of signaling adaptors. Autophagy flux inhibitors (e.g., bafilomycin A1) help confirm degradation routes [4,5].
How CRISPR Can Be Used to Study GO:0032688 negative regulation of interferon-beta production
Knockout
CRISPR knockout of candidate negative regulators (e.g., SESN1, TRIM13, YTHDF2) can be used to test whether loss of function enhances IFN-beta production. Such models are valuable for validating gene function in innate immunity [2,4,5].
Point Mutation
Point mutations can be introduced to abrogate specific post-translational modification sites (e.g., lactylation site in HSPA6) or catalytic residues, allowing precise dissection of molecular mechanisms.
Knock-in
Knock-in of epitope tags (e.g., HA, GFP) or reporter genes enables visualization and biochemical analysis of endogenous proteins, such as tracking MAVS degradation or STING1 trafficking [4,5].
Overexpression
Overexpression of candidate negative regulators (e.g., TRIM13, YTHDF2) can suppress IFN-beta production, confirming their inhibitory role and facilitating downstream signaling studies [2,5].
How EDITGENE Supports negative regulation of interferon-beta production Research
Researchers studying negative regulation of interferon-beta production-related genes often need to determine whether a candidate gene is causally involved in suppressing IFN-beta, and to dissect the precise molecular mechanism. EDITGENE provides comprehensive CRISPR-based services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of interferon-beta production research.
Frequently Asked Questions About negative regulation of interferon-beta production
What is GO:0032688?
GO:0032688 is the Gene Ontology term for negative regulation of interferon-beta production, describing any process that stops, prevents, or reduces the frequency, rate, or extent of IFN-beta production.
What genes are involved in negative regulation of interferon-beta production?
Key genes include SESN1, TRIM13, YTHDF2, HSPA6, KEAP1, TRAF3, and feedback regulators like SOCS1/3 and USP18 [1,2,3,4,5,7,8].
How do viruses evade IFN-beta production?
Viruses such as FMDV and PRRSV exploit negative regulatory mechanisms, including degradation of YTHDF2 or lactylation of HSPA6, to suppress IFN-beta [2,3].
What is the role of autophagy in IFN-beta negative regulation?
Autophagy mediates the degradation of signaling adaptors like MAVS and STING1, thereby shutting down IFN-beta production [4,5].
Which metabolites suppress IFN-beta production?
Itaconate and lactate are metabolites that suppress IFN-beta production via KEAP1-Nrf2 activation and HSPA6 lactylation, respectively [1,3].
How can I study negative regulation of IFN-beta production?
Common methods include IFN-beta luciferase reporters, RNA-seq, proteomics, and CRISPR knockout or overexpression models [4,6].
What diseases are associated with dysregulated IFN-beta negative regulation?
Viral persistence, autoimmune interferonopathies, and cancer immune evasion are linked to altered negative regulation of IFN-beta [2,3,8].
What is the definition of negative regulation of interferon-beta production?
It is any process that reduces or prevents the production of interferon-beta, a type I interferon critical for antiviral defense.
Can CRISPR be used to study IFN-beta negative regulators?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression are powerful approaches to dissect gene function in this pathway [2,4,5].
Why is negative regulation of IFN-beta important for immune homeostasis?
It prevents excessive inflammation and autoimmunity while allowing effective antiviral responses, maintaining a balanced immune state.
Conclusion
Negative regulation of interferon-beta production (GO:0032688) is a critical immune checkpoint that balances antiviral defense with prevention of immunopathology. Diverse mechanisms, from metabolite sensing to selective autophagy, converge to suppress IFN-beta, and their dysregulation contributes to viral persistence, autoimmunity, and cancer. CRISPR-based models are indispensable for dissecting these pathways and identifying therapeutic targets. EDITGENE offers a full suite of services to support research on this important process.
References
- 1. Mills EL et al.. 2018. Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1.. Nature 556(7699):113-117 PMID: 29590092
- 2. Liu H et al.. 2024. Foot-and-mouth disease virus VP1 degrades YTHDF2 through autophagy to regulate IRF3 activity for viral replication.. Autophagy 20(7):1597-1615 PMID: 38516932
- 3. Pang Y et al.. 2024. Lactate-lactylation-HSPA6 axis promotes PRRSV replication by impairing IFN-β production.. J Virol 98(1):e0167023 PMID: 38088561
- 4. Xu L et al.. 2025. SESN1 negatively regulates STING1 to maintain innate immune homeostasis.. Autophagy 21(6):1245-1262 PMID: 39945079
- 5. Zhou P et al.. 2025. Avian TRIM13 attenuates antiviral innate immunity by targeting MAVS for autophagic degradation.. Autophagy 21(4):754-770 PMID: 39508267
- 6. Ye J et al.. 2011. Negative regulation of interferon-β gene expression during acute and persistent virus infections.. PLoS One 6(6):e20681 PMID: 21677781
- 7. Wei X et al.. 2018. Negative Regulation of Interferon-β Production by Alternative Splicing of Tumor Necrosis Factor Receptor-Associated Factor 3 in Ducks.. Front Immunol 9:409 PMID: 29599773
- 8. Arimoto KI et al.. 2018. Negative regulation of type I IFN signaling.. J Leukoc Biol PMID: 29357192
